AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX - AROA BIOSURGERY LIMITED

Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.93
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.595

19 Jul
2024

-0.005

OPEN

$0.62

-0.83%

HIGH

$0.62

12,444

LOW

$0.60

TARGET
$0.975 63.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY25
Forecast
FY26
Forecast
EPS (cps) 0.8 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 75.7 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-2.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx64.0 M
Book Value Per Share xxxxxxxxxxxxxxx25.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.8 M
Net Profit Margin xxxxxxxxxxxxxxx-15.39 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.81 %
Return on Invested Capital xxxxxxxxxxxxxxx-10.14 %
Return on Assets xxxxxxxxxxxxxxx-9.35 %
Return on Equity xxxxxxxxxxxxxxx-10.81 %
Return on Total Capital xxxxxxxxxxxxxxx-11.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx28 M
Price To Book Value xxxxxxxxxxxxxxx2.19

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.5 M
Capex % of Sales xxxxxxxxxxxxxxx10.11 %
Cost of Goods Sold xxxxxxxxxxxxxxx9 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx66 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

22/05/2024

1

Add

$1.05

76.47%

Aroa Biosurgery's FY24 revenue was in line with guidance though the EBITDA loss of -NZ$3.1m was higher than the -NZ$2.1m expected by Morgans. Myriad sales continue to grow and be a key focus for the group, note the analysts.

Importantly, according to the broker, management provided FY25 guidance for revenue of NZ$80-87m and normalised EBITDA of NZ$2-6m.

The Add rating is unchanged and the broker's target falls to $1.05 from $1.20 due to lower earnings forecasts (on average by -18%) across the forecast period reflecting a higher cost base.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.92 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 3.69 cents.

EXPERT VIEWS
Display All Commentary

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

29/05/2024

1

Buy

$1.00

68.07%

As the FY24 results were in line with expectations, showing a total revenue of NZ$69.1m and an EBITDA loss of -NZ$3.1m, Canaccord Genuity has retained its Buy rating for Aroa Biosurgery with an unchanged price target of $1.

As per the broker's comments, strong Myriad sales growth of 73% was noted, though OviTex sales were down -7% YoY. The broker anticipates FY25 to be Aroa’s first profitable year, driven by increased sales productivity and scale, with an expected revenue range of NZ$80-87m.

FY25 EBITDA forecast has been adjusted to NZ$2.4m from NZ$4.3m and FY26 to NZ$14.0m from NZ$11.0m.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.37 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.94 cents.

Jarden

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

ARX STOCK CHART